Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)

NCT04235114 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Colorectal Cancer

Interventions

DRUG: 50 mg 89Zr-DFO-Nimotuzumab
DRUG: 1 mg 89Zr-DFO-Nimotuzumab

Sponsor

University of Saskatchewan